Immune Sensitivity Links Race and Survival After Prostate Cancer Immunotherapy

Prostate cancer researchers at the Duke Cancer Institute (DCI) have published a new study that may solve one of the mysteries of advanced metastatic prostate cancer:  why do Black men experience a greater survival benefit from a personalized immunotherapy called sipuleucel-T immunotherapy than white men, when both groups have cancer that is resistant to hormonal therapy?  Until now, the reasons baffled clinicians and researchers at the Duke Cancer Institute center for Prostate and Urologic Cancers.

DPUC members who are authors include Andrew Armstrong, MD; Michael Brown, PhD; and Smita Nair, PhD.

Read More